Exscientia Plc American Depositary Shares EXAI · Stock Open Exscientia Plc American Depositary Shares in new tab
Exscientia Plc American Depositary Shares Analysis (EXAI)
Is Exscientia Plc American Depositary Shares a good investment? Exscientia Plc American Depositary Shares (EXAI) is currently trading at 4.84 USD. Market analysts have a consensus price target of 5.35 USD. This suggests a potential upside from current levels.
Investor FAQ
Does Exscientia Plc American Depositary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Exscientia Plc American Depositary Shares?
Exscientia Plc American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Community Discussion